Steve Lianoglou

Steve Lianoglou

Auto-generated profile, based on publicly available information

Steve Lianoglou

ReviR Therapeutics Inc., Brisbane, California, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2018 in Nature
Verified
Journal Article
Closed access
PDF file
SMSanjeev Mariathasan
Sanjeev Mariathasan
STShannon J. Turley
Shannon J. Turley
DNDorothee Nickles
Dorothee Nickles
ACAlessandra Castiglioni
Alessandra Castiglioni
KYKobe Yuen
Kobe Yuen
TPThomas Powles
Thomas Powles

1 March 2020 in Neuron
Verified
Journal Article
Closed access
ANAlicia A. Nugent
Alicia A. Nugent
KLKarin Lin
Karin Lin
BLBettina van Lengerich
Bettina van Lengerich
SLSteve Lianoglou
Steve Lianoglou
LPLaralynne Przybyla
Laralynne Przybyla
GPGilbert Di Paolo
Gilbert Di Paolo

21 October 2013 in Genes & Development
Verified
Journal Article
Open access
PDF file
SLSteve Lianoglou
Steve Lianoglou
VGVidur Garg
Vidur Garg
JYJulie L. Yang
Julie L. Yang
CLChristina S. Leslie
Christina S. Leslie
CMChristine Mayr
Christine Mayr
More than half of human genes use alternative cleavage and polyadenylation (ApA) to generate mRNA transcripts that differ in the lengths of their 3′ untranslated regions (UTRs), thus altering the post-transcriptional fate of the message and likely the protein output. The extent of 3′ UTR variation across tissues and the functional role of ApA remain poorly understood. We developed a sequencing method called 3′-seq to quantitatively map the 3′ ends of the transcriptome of diverse human tissues and isogenic transformation systems. We found that cell type-specific gene expression is accomplished by two complementary programs. Tissue-restricted genes tend to have single 3′ UTRs, whereas a majority of ubiquitously transcribed genes generate multiple 3′ UTRs. During transformation and differentiation, single-UTR genes change their mRNA abundance levels, while multi-UTR genes mostly change 3′ UTR isoform ratios to achieve tissue specificity. However, both regulation programs target genes that function in the same pathways and processes that characterize the new cell type. Instead of finding global shifts in 3′ UTR length during transformation and differentiation, we identify tissue-specific groups of multi-UTR genes that change their 3′ UTR ratios; these changes in 3′ UTR length are largely independent from changes in mRNA abundance. Finally, tissue-specific usage of ApA sites appears to be a mechanism for changing the landscape targetable by ubiquitously expressed microRNAs.

21 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJanet Lau
Janet Lau
JCJeanne Cheung
Jeanne Cheung
ANArmando Navarro
Armando Navarro
SLSteve Lianoglou
Steve Lianoglou
BHBenjamin Haley
Benjamin Haley
MSMaike Schmidt
Maike Schmidt
Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune system. Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has produced unparalleled, durable clinical responses, with highest likelihood of response seen in patients whose tumour or immune cells express PD-L1 before therapy. The significance of PD-L1 expression in each cell type has emerged as a central and controversial unknown in the clinical development of immunotherapeutics. Using genetic deletion in preclinical mouse models, here we show that PD-L1 from disparate cellular sources, including tumour cells, myeloid or other immune cells can similarly modulate the degree of cytotoxic T-cell function and activity in the tumour microenvironment. PD-L1 expression in both the host and tumour compartment contribute to immune suppression in a non-redundant fashion, suggesting that both sources could be predictive of sensitivity to therapeutic agents targeting the PD-L1/PD-1 axis.

18 May 2016 in Nature
Verified
Journal Article
Closed access
PHPeter M. Haverty
Peter M. Haverty
ELEva Lin
Eva Lin
JTJenille Tan
Jenille Tan
YYYihong Yu
Yihong Yu
BLBilly Lam
Billy Lam
RBRichard Bourgon
Richard Bourgon

12 January 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
BLBettina van Lengerich
Bettina van Lengerich
LZLihong Zhan
Lihong Zhan
DXDan Xia
Dan Xia
DCDarren Chan
Darren Chan
DJDavid Joy
David Joy
KMKathryn M. Monroe
Kathryn M. Monroe
Loss-of-function variants of TREM2 are associated with increased risk of Alzheimer’s disease (AD), suggesting that activation of this innate immune receptor may be a useful therapeutic strategy. Here we describe a high-affinity human TREM2-activating antibody engineered with a monovalent transferrin receptor (TfR) binding site, termed antibody transport vehicle (ATV), to facilitate blood–brain barrier transcytosis. Upon peripheral delivery in mice, ATV:TREM2 showed improved brain biodistribution and enhanced signaling compared to a standard anti-TREM2 antibody. In human induced pluripotent stem cell (iPSC)-derived microglia, ATV:TREM2 induced proliferation and improved mitochondrial metabolism. Single-cell RNA sequencing and morphometry revealed that ATV:TREM2 shifted microglia to metabolically responsive states, which were distinct from those induced by amyloid pathology. In an AD mouse model, ATV:TREM2 boosted brain microglial activity and glucose metabolism. Thus, ATV:TREM2 represents a promising approach to improve microglial function and treat brain hypometabolism found in patients with AD.